NARSAD


Study Description: The purpose of this study is to test a possible new treatment for schizophrenia and schizoaffective disorder using tocilizumab versus placebo in a 12 week trial to determine its effects on symptoms, especially cognition.

Contact for Enrollment

    
     (706) 721-4445
    BRMiller@augusta.edu

    Submit Information Online

Principal Investigator: Brian Miller

Eligibility Criteria: Males and Females between ages 18 and 55 DIagnosis of Schizophrenia or Schizoaffective Disorder No Psychiatric hospitalizations in the past 3 months

Compensation: Yes, subjects will be compensated.

Compensation Explanation: Subjects will receive a check in the amount of: $50 for completing the first (Screening) visit, $100 for completing the second visit (Baselinevisit and first Tocilizumab infusion), $50 for completing the third visit (2 week follow-up), $100 for completing the fourth visit (4 week follow up and second Tocilizumab infusion), $100 for completing the fifth visit (8 weekfollow-up and third Tocilizumab infusion), and $100 for completing the sixth visit (12 week follow-up) in this study. Subjects will be responsible for the costs of transportation to participate in the study.

 

Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.